Vycor Medical INC

Vycor Medical reports a 5% revenue increase and improved operating profitability for the first quarter of 2026.

Vycor Medical, Inc. announced its financial results for the year ended December 31, 2025, reporting an 18% increase in Vycor Medical division revenues and a return to operating profit.

Vycor Medical, Inc. announced significant revenue growth and a return to operating profit for the three and nine months ended September 30, 2025, driven by its Vycor Medical division.

Vycor Medical announced significant revenue and operating profit increases for Q2 2025, driven by international expansion of its neurosurgery division.

Vycor Medical announces a 30% increase in revenue for the first quarter of 2025, primarily driven by international sales growth in its Vycor Medical division.

Vycor Medical, Inc. announces its financial results for the year ended December 31, 2024, highlighting a 9% increase in revenue driven by growth in its Vycor Medical division.

Vycor Medical reported a net income of $20,108 for the first quarter of 2026, though substantial doubt remains regarding its ability to continue as a going concern.

Vycor Medical reported improved revenue and reduced net losses for Q3 and the nine months ended September 30, 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Vycor Medical, Inc. reported increased revenue and reduced net loss for Q2 2025, but faces significant liquidity challenges and a 'going concern' warning.

Vycor Medical's Q1 2025 shows revenue growth of 30% year-over-year, but the company continues to face net losses and substantial doubt about its ability to continue as a going concern.

Vycor Medical saw a 27% increase in revenue compared to the same quarter last year, driven by growth in its neurosurgical device division, while facing ongoing concerns about its ability to continue as a going concern.

Vycor Medical's Q2 2024 results show a decrease in revenue compared to the same period last year, alongside ongoing concerns about the company's ability to continue as a going concern.

Vycor Medical reported increased revenue and reduced net losses in 2025, driven by international growth, but faces substantial doubt about its ability to continue as a going concern.

Vycor Medical's 2024 10-K filing reveals a revenue increase driven by US sales, but also highlights concerns about the company's ability to continue as a going concern due to accumulated losses and working capital deficiency.

Vycor Medical, Inc. saw a 22% increase in revenue for its medical device sales in 2023 and achieved positive cash operating income for the year.